The acceptability of nanocarriers for drug delivery in different contexts of use: perceptions of researchers and research trainees in the field of new technologies.
Identifieur interne : 000176 ( Main/Exploration ); précédent : 000175; suivant : 000177The acceptability of nanocarriers for drug delivery in different contexts of use: perceptions of researchers and research trainees in the field of new technologies.
Auteurs : Vanessa Chenel [France] ; Patrick Boissy [Canada] ; Marie-Sol Poirier [Canada] ; Jean-Pierre Cloarec [France] ; Johane Patenaude [Canada]Source :
- International journal of nanomedicine [ 1178-2013 ] ; 2015.
Descripteurs français
- KwdFr :
- ADN (administration et posologie), Canada, Connaissances, attitudes et pratiques en santé, Enquêtes et questionnaires, Europe, Grippe humaine (traitement médicamenteux), Humains, Nanomédecine (), Nanostructures, Perception, Personnel de recherche, Systèmes de délivrance de médicaments (), Tumeurs du poumon (traitement médicamenteux), Vecteurs de médicaments (), Vecteurs de médicaments (administration et posologie).
- MESH :
- administration et posologie : ADN, Vecteurs de médicaments.
- traitement médicamenteux : Grippe humaine, Tumeurs du poumon.
- Canada, Connaissances, attitudes et pratiques en santé, Enquêtes et questionnaires, Europe, Humains, Nanomédecine, Nanostructures, Perception, Personnel de recherche, Systèmes de délivrance de médicaments, Vecteurs de médicaments.
English descriptors
- KwdEn :
- Canada, DNA (administration & dosage), Drug Carriers (administration & dosage), Drug Carriers (chemistry), Drug Delivery Systems (methods), Europe, Health Knowledge, Attitudes, Practice, Humans, Influenza, Human (drug therapy), Lung Neoplasms (drug therapy), Nanomedicine (methods), Nanostructures, Perception, Research Personnel, Surveys and Questionnaires.
- MESH :
- chemical , administration & dosage : DNA, Drug Carriers.
- chemical , chemistry : Drug Carriers.
- drug therapy : Influenza, Human, Lung Neoplasms.
- methods : Drug Delivery Systems, Nanomedicine.
- Canada, Europe, Health Knowledge, Attitudes, Practice, Humans, Nanostructures, Perception, Research Personnel, Surveys and Questionnaires.
Abstract
BACKGROUND
Despite marked optimism in the field of nanomedicine about the use of drug-delivery nanocarriers, uncertainties exist concerning nanocarriers' possible unintended impacts and effects. These uncertainties could affect user acceptance and acceptability. "Acceptance" refers to the intention to put a technology or a device to a specified use. "Acceptability" refers to a value judgment that accounts for acceptance. The objectives of this study were to characterize impact perception, acceptance, and acceptability in relation to drug-delivery nanocarriers in different contexts of use, and to explore relationships among these concepts.
METHODS
A sample of European and Canadian researchers and graduate research trainees active in the field of new technologies was recruited by targeted email invitation for participation in a web-based questionnaire study. The questionnaire presented scenarios for two contexts of use (lung cancer, seasonal flu) of drug-delivery nanocarriers with two compositions (carbon, synthetic DNA). Respondents' impact perception, acceptance, and acceptability judgment in relation to each kind of nanocarrier in each context of use were measured with Likert scale questions and scored using categorical values.
RESULTS
Two hundred and fourteen researchers and graduate research trainees completed the questionnaire. The results showed that nanocarrier composition influenced impact perception: as compared with the carbon nanocarrier impact perception, the positive impacts of the synthetic DNA nanocarrier were perceived as more significant and more likely to occur than its negative impacts. Composition did not influence acceptance or acceptability. Context of use significantly influenced acceptance and acceptability of both kinds of nanocarriers: researchers were more likely to accept the use of nanocarriers to treat lung cancer than the seasonal flu. The results also showed a significant relationship between acceptance and the perceived usefulness of the treatments.
CONCLUSION
Nanocarrier composition does not appear to influence acceptance or acceptability. On the other hand, the nanocarriers' perceived usefulness and context of use are both major factors in accounting for acceptance and acceptability.
DOI: 10.2147/IJN.S78799
PubMed: 25844040
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The acceptability of nanocarriers for drug delivery in different contexts of use: perceptions of researchers and research trainees in the field of new technologies.</title><author><name sortKey="Chenel, Vanessa" sort="Chenel, Vanessa" uniqKey="Chenel V" first="Vanessa" last="Chenel">Vanessa Chenel</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon</wicri:regionArea><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion></affiliation></author><author><name sortKey="Boissy, Patrick" sort="Boissy, Patrick" uniqKey="Boissy P" first="Patrick" last="Boissy">Patrick Boissy</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke</wicri:regionArea><wicri:noRegion>Université de Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Poirier, Marie Sol" sort="Poirier, Marie Sol" uniqKey="Poirier M" first="Marie-Sol" last="Poirier">Marie-Sol Poirier</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke</wicri:regionArea><wicri:noRegion>Université de Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Cloarec, Jean Pierre" sort="Cloarec, Jean Pierre" uniqKey="Cloarec J" first="Jean-Pierre" last="Cloarec">Jean-Pierre Cloarec</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon</wicri:regionArea><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion></affiliation></author><author><name sortKey="Patenaude, Johane" sort="Patenaude, Johane" uniqKey="Patenaude J" first="Johane" last="Patenaude">Johane Patenaude</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke</wicri:regionArea><wicri:noRegion>Université de Sherbrooke</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25844040</idno><idno type="pmid">25844040</idno><idno type="doi">10.2147/IJN.S78799</idno><idno type="wicri:Area/Main/Corpus">000215</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000215</idno><idno type="wicri:Area/Main/Curation">000215</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000215</idno><idno type="wicri:Area/Main/Exploration">000215</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The acceptability of nanocarriers for drug delivery in different contexts of use: perceptions of researchers and research trainees in the field of new technologies.</title><author><name sortKey="Chenel, Vanessa" sort="Chenel, Vanessa" uniqKey="Chenel V" first="Vanessa" last="Chenel">Vanessa Chenel</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon</wicri:regionArea><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion></affiliation></author><author><name sortKey="Boissy, Patrick" sort="Boissy, Patrick" uniqKey="Boissy P" first="Patrick" last="Boissy">Patrick Boissy</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke</wicri:regionArea><wicri:noRegion>Université de Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Poirier, Marie Sol" sort="Poirier, Marie Sol" uniqKey="Poirier M" first="Marie-Sol" last="Poirier">Marie-Sol Poirier</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke</wicri:regionArea><wicri:noRegion>Université de Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Cloarec, Jean Pierre" sort="Cloarec, Jean Pierre" uniqKey="Cloarec J" first="Jean-Pierre" last="Cloarec">Jean-Pierre Cloarec</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon</wicri:regionArea><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion><wicri:noRegion>site École Centrale de Lyon</wicri:noRegion></affiliation></author><author><name sortKey="Patenaude, Johane" sort="Patenaude, Johane" uniqKey="Patenaude J" first="Johane" last="Patenaude">Johane Patenaude</name><affiliation wicri:level="1"><nlm:affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke</wicri:regionArea><wicri:noRegion>Université de Sherbrooke</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of nanomedicine</title><idno type="eISSN">1178-2013</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada</term><term>DNA (administration & dosage)</term><term>Drug Carriers (administration & dosage)</term><term>Drug Carriers (chemistry)</term><term>Drug Delivery Systems (methods)</term><term>Europe</term><term>Health Knowledge, Attitudes, Practice</term><term>Humans</term><term>Influenza, Human (drug therapy)</term><term>Lung Neoplasms (drug therapy)</term><term>Nanomedicine (methods)</term><term>Nanostructures</term><term>Perception</term><term>Research Personnel</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN (administration et posologie)</term><term>Canada</term><term>Connaissances, attitudes et pratiques en santé</term><term>Enquêtes et questionnaires</term><term>Europe</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Nanomédecine ()</term><term>Nanostructures</term><term>Perception</term><term>Personnel de recherche</term><term>Systèmes de délivrance de médicaments ()</term><term>Tumeurs du poumon (traitement médicamenteux)</term><term>Vecteurs de médicaments ()</term><term>Vecteurs de médicaments (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>DNA</term><term>Drug Carriers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Drug Carriers</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>ADN</term><term>Vecteurs de médicaments</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term><term>Nanomedicine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Canada</term><term>Europe</term><term>Health Knowledge, Attitudes, Practice</term><term>Humans</term><term>Nanostructures</term><term>Perception</term><term>Research Personnel</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Canada</term><term>Connaissances, attitudes et pratiques en santé</term><term>Enquêtes et questionnaires</term><term>Europe</term><term>Humains</term><term>Nanomédecine</term><term>Nanostructures</term><term>Perception</term><term>Personnel de recherche</term><term>Systèmes de délivrance de médicaments</term><term>Vecteurs de médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Despite marked optimism in the field of nanomedicine about the use of drug-delivery nanocarriers, uncertainties exist concerning nanocarriers' possible unintended impacts and effects. These uncertainties could affect user acceptance and acceptability. "Acceptance" refers to the intention to put a technology or a device to a specified use. "Acceptability" refers to a value judgment that accounts for acceptance. The objectives of this study were to characterize impact perception, acceptance, and acceptability in relation to drug-delivery nanocarriers in different contexts of use, and to explore relationships among these concepts.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A sample of European and Canadian researchers and graduate research trainees active in the field of new technologies was recruited by targeted email invitation for participation in a web-based questionnaire study. The questionnaire presented scenarios for two contexts of use (lung cancer, seasonal flu) of drug-delivery nanocarriers with two compositions (carbon, synthetic DNA). Respondents' impact perception, acceptance, and acceptability judgment in relation to each kind of nanocarrier in each context of use were measured with Likert scale questions and scored using categorical values.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Two hundred and fourteen researchers and graduate research trainees completed the questionnaire. The results showed that nanocarrier composition influenced impact perception: as compared with the carbon nanocarrier impact perception, the positive impacts of the synthetic DNA nanocarrier were perceived as more significant and more likely to occur than its negative impacts. Composition did not influence acceptance or acceptability. Context of use significantly influenced acceptance and acceptability of both kinds of nanocarriers: researchers were more likely to accept the use of nanocarriers to treat lung cancer than the seasonal flu. The results also showed a significant relationship between acceptance and the perceived usefulness of the treatments.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Nanocarrier composition does not appear to influence acceptance or acceptability. On the other hand, the nanocarriers' perceived usefulness and context of use are both major factors in accounting for acceptance and acceptability.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25844040</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1178-2013</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>International journal of nanomedicine</Title><ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation></Journal><ArticleTitle>The acceptability of nanocarriers for drug delivery in different contexts of use: perceptions of researchers and research trainees in the field of new technologies.</ArticleTitle><Pagination><MedlinePgn>2125-37; quiz 2138-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S78799</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite marked optimism in the field of nanomedicine about the use of drug-delivery nanocarriers, uncertainties exist concerning nanocarriers' possible unintended impacts and effects. These uncertainties could affect user acceptance and acceptability. "Acceptance" refers to the intention to put a technology or a device to a specified use. "Acceptability" refers to a value judgment that accounts for acceptance. The objectives of this study were to characterize impact perception, acceptance, and acceptability in relation to drug-delivery nanocarriers in different contexts of use, and to explore relationships among these concepts.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A sample of European and Canadian researchers and graduate research trainees active in the field of new technologies was recruited by targeted email invitation for participation in a web-based questionnaire study. The questionnaire presented scenarios for two contexts of use (lung cancer, seasonal flu) of drug-delivery nanocarriers with two compositions (carbon, synthetic DNA). Respondents' impact perception, acceptance, and acceptability judgment in relation to each kind of nanocarrier in each context of use were measured with Likert scale questions and scored using categorical values.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two hundred and fourteen researchers and graduate research trainees completed the questionnaire. The results showed that nanocarrier composition influenced impact perception: as compared with the carbon nanocarrier impact perception, the positive impacts of the synthetic DNA nanocarrier were perceived as more significant and more likely to occur than its negative impacts. Composition did not influence acceptance or acceptability. Context of use significantly influenced acceptance and acceptability of both kinds of nanocarriers: researchers were more likely to accept the use of nanocarriers to treat lung cancer than the seasonal flu. The results also showed a significant relationship between acceptance and the perceived usefulness of the treatments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nanocarrier composition does not appear to influence acceptance or acceptability. On the other hand, the nanocarriers' perceived usefulness and context of use are both major factors in accounting for acceptance and acceptability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chenel</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boissy</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Marie-Sol</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cloarec</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada ; Université de Lyon, Institut des Nanotechnologies de Lyon (INL), site École Centrale de Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patenaude</LastName><ForeName>Johane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Institute for Technological Innovation (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada ; Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada ; Laboratoire Nanotechnologies et Nanosystèmes (LN2), Centre National de la Recherche Scientifique (CNRS), Université de Sherbrooke, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Nanomedicine</MedlineTA><NlmUniqueID>101263847</NlmUniqueID><ISSNLinking>1176-9114</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="Y">Drug Carriers</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010465" MajorTopicYN="N">Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012108" MajorTopicYN="N">Research Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">E3LS</Keyword><Keyword MajorTopicYN="N">ELSI</Keyword><Keyword MajorTopicYN="N">acceptance</Keyword><Keyword MajorTopicYN="N">impact perception</Keyword><Keyword MajorTopicYN="N">nanomedicine</Keyword><Keyword MajorTopicYN="N">researchers’ perceptions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25844040</ArticleId><ArticleId IdType="doi">10.2147/IJN.S78799</ArticleId><ArticleId IdType="pii">ijn-10-2125</ArticleId><ArticleId IdType="pmc">PMC4368030</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Risk Anal. 2004 Feb;24(1):185-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15028010</ArticleId></ArticleIdList></Reference><Reference><Citation>Appetite. 2007 Sep;49(2):459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">17442455</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2006 Dec 1;58(14):1456-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17070960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jan-Feb;1(1):2-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20049773</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nanomedicine. 2011;6:3473-85</Citation><ArticleIdList><ArticleId IdType="pubmed">22267931</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine (Lond). 2011 Jun;6(4):681-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21506689</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk Anal. 2005 Jun;25(3):567-88</Citation><ArticleIdList><ArticleId IdType="pubmed">16022691</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nanomedicine. 2010;5:803-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21042425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Eng Ethics. 2015 Apr;21(2):293-315</Citation><ArticleIdList><ArticleId IdType="pubmed">24728612</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2006 Oct;24(10):1211-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17033654</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk Anal. 2007 Feb;27(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17362400</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Apr 17;236(4799):280-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3563507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Inform. 2010 Feb;43(1):159-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19615467</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2005 Mar;19(3):311-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15746175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine (Lond). 2014 Jul;9(10):1475-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25253496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Chenel, Vanessa" sort="Chenel, Vanessa" uniqKey="Chenel V" first="Vanessa" last="Chenel">Vanessa Chenel</name></noRegion><name sortKey="Cloarec, Jean Pierre" sort="Cloarec, Jean Pierre" uniqKey="Cloarec J" first="Jean-Pierre" last="Cloarec">Jean-Pierre Cloarec</name></country><country name="Canada"><noRegion><name sortKey="Boissy, Patrick" sort="Boissy, Patrick" uniqKey="Boissy P" first="Patrick" last="Boissy">Patrick Boissy</name></noRegion><name sortKey="Patenaude, Johane" sort="Patenaude, Johane" uniqKey="Patenaude J" first="Johane" last="Patenaude">Johane Patenaude</name><name sortKey="Poirier, Marie Sol" sort="Poirier, Marie Sol" uniqKey="Poirier M" first="Marie-Sol" last="Poirier">Marie-Sol Poirier</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000176 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000176 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25844040
|texte= The acceptability of nanocarriers for drug delivery in different contexts of use: perceptions of researchers and research trainees in the field of new technologies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25844040" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |